FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 667 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers May 2, 2018 Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... September 9, 2025 Front-line CS1001 Plus Platinum-Based Chemotherapy Delivers Substantial Benefit in Advanced Non-Small... November 21, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Daratumumab Clinical Benefit and Safety of Encorafenib Plus Binimetinib in Treatment-Naïve and... EMA Recommends Granting a Conditional Marketing Authorisation for Mirdametinib Coping with COVID: New Stimulus Funds and Unemployment Benefit Update
